Physician profile
Hammad Malik
NPI 1629063904
$34,694.13
in general payments reported to CMS, 2019-2025
32 companies · $6,087 in 2025
The $6,087 reported for 2025 was more than what 92% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,942 · 2020: $5,252 · 2021: $2,600 · 2022: $3,314 · 2023: $6,030 · 2024: $6,470 · 2025: $6,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Travel and Lodging: $1,460 · Education: $63.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,062.52 |
| Travel and Lodging | $1,460.30 |
| Education | $63.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $11,387.21 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16, Superion Indirect Decompression System |
| Abbott Laboratories | $10,095.39 | 2019-2025 | Proclaim, Eterna |
| Biotronik Nro, INC. | $3,032.13 | 2023-2025 | Prospera, Biotronik |
| Medtronic USA, INC. | $2,366.76 | 2019-2020 | |
| Nevro Corp. | $2,350.90 | 2019-2024 | Senza |
| Saluda Medical Americas, INC. | $1,503.67 | 2023-2025 | Evoke, Evoke Scs |
| Globus Medical, INC. | $1,087.41 | 2025 | Senza, Vyrsa V1 |
| Medtronic, INC. | $806.70 | 2021-2025 | Inceptiv |
| Vertos Medical, INC. | $509.76 | 2020-2024 | Mild Device Kit |
| Collegium Pharmaceutical, INC. | $264.78 | 2021-2025 | Xtampza, Belbuca |
| Curonix LLC | $229.82 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Teva Pharmaceuticals USA, INC. | $182.41 | 2019-2021 | |
| Stryker Corporation | $172.01 | 2024 | Mild Device Kit |
| Amgen INC. | $91.46 | 2019-2022 | |
| Painteq LLC | $73.71 | 2023 | Painteq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.09 | 2023-2025 | Relistor |
| Pfizer INC. | $71.49 | 2019-2020 | |
| Foundation Fusion Solutions, LLC | $65.68 | 2025 | |
| Scilex Pharmaceuticals INC. | $51.74 | 2019-2023 | Ztlido |
| Azurity Pharmaceuticals, INC. | $45.55 | 2023-2025 | Horizant, Horizant |
| Abbvie INC. | $44.67 | 2022-2024 | |
| Biodelivery Sciences International, INC. | $27.68 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $22.52 | 2025 | Iovera, Zilretta |
| Mdd US Operations, LLC | $21.47 | 2020 | |
| Grt US Holding, INC. | $18.84 | 2021 | |
| Convatec INC. | $17.44 | 2024 | |
| Forte Bio-Pharma LLC | $15.96 | 2025 | Prolate, Tanlor, Nalocet |
| Si-Bone, INC. | $14.14 | 2020 | |
| Spinal Simplicity, LLC | $13.60 | 2024 | Ha Minuteman G3-R |
| Flowonix Medical Incorporated | $12.93 | 2020 | |
| Horizon Therapeutics Plc | $12.05 | 2020 | |
| Daiichi Sankyo INC. | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hammad Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.